Alzamend Neuro Files Definitive Proxy for Reverse Stock Split and Highly Dilutive Equity Plans
ALZN sits 32% above its 52-week low of $1.58.
Summary
Alzamend Neuro filed a definitive proxy statement proposing a reverse stock split to maintain Nasdaq listing and seeking approval for highly dilutive equity incentive plans and officer option grants, totaling over 67% potential dilution.
Key Events · Corporate Governance and Compliance · ALZN
-
Reverse Stock Split Proposed
Shareholders will vote on a reverse stock split with a ratio between 1-for-2 and 1-for-10, aimed at increasing the stock price to meet Nasdaq listing requirements. This follows the preliminary proxy filed on 2026-02-09.
-
New Equity Incentive Plan
The company seeks approval for a 2025 Stock Incentive Plan authorizing the issuance of 1.6 million shares, representing approximately 42.05% potential dilution based on current outstanding shares.
-
Significant Officer & Director Option Grants
Approval is sought for the issuance of 970,000 stock options to directors and executive officers at an exercise price of $2.36 per share. This represents an additional 25.49% potential dilution. The options are currently out-of-the-money compared to the current stock price of $2.08.
-
Substantial Combined Dilution
The new equity incentive plan and officer option grants combined represent a potential dilution of over 67% to existing shareholders if all shares are issued.
Analysis · ALZN · Life Sciences
Alzamend Neuro has filed its definitive proxy statement for its annual meeting, outlining critical proposals that could significantly impact its capital structure and shareholder value. The company is seeking approval for a reverse stock split with a ratio between 1-for-2 and 1-for-10, primarily to maintain its Nasdaq Capital Market listing. This action, while necessary for compliance, often signals underlying financial challenges and is generally viewed negatively by the market. Additionally, shareholders will vote on a new 2025 Stock Incentive Plan authorizing 1.6 million shares and separate equity issuances of 970,000 options to directors and executive officers. Combined, these proposals represent a potential dilution of over 67% relative to current outstanding shares. While the new options are currently out-of-the-money (exercise price of $2.36 vs. current stock price of $2.08), the sheer volume of potential new shares is substantial for a company with a market capitalization of approximately $7.9 million. Investors should closely monitor the outcome of these votes, as the significant potential dilution and the need for a reverse split highlight the company's precarious financial position and its efforts to secure future capital and maintain market presence.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 44% of the 562 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALZN was trading at $2.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $1.58 to $10.17. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.